2023 PreprintHelp me understand this report
Supplementary Figure S1 from Novel Oral mTORC1/2 Inhibitor TAK-228 Has Synergistic Antitumor Effects When Combined with Paclitaxel or PI3Kα Inhibitor TAK-117 in Preclinical Bladder Cancer Models
Abstract: <p>Cellular effects of TAK-228 on human bladder cancer cell lines.</p>
View published versions
This publication either has no citations yet, or we are still processing them
Set email alert for when this publication receives citations?
See others like this or search for similar articles
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
